Nystatin

Cat. No.: HY-17409
CAS No.: 1400-61-9
Molecular Formula: C_{47}H_{75}NO_{17}
Molecular Weight: 926.09
Target: Fungal
Pathway: Anti-infection
Storage: -20°C, protect from light
* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (53.99 mM; Need ultrasonic)

<table>
<thead>
<tr>
<th>Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>1.0798 mL</td>
<td>5.3990 mL</td>
<td>10.7981 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.2160 mL</td>
<td>1.0798 mL</td>
<td>2.1596 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.1080 mL</td>
<td>0.5399 mL</td>
<td>1.0798 mL</td>
</tr>
</tbody>
</table>

Preparation of Stock Solutions

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (2.70 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (2.70 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Nystatin is a polyene antifungal antibiotic effective against yeast and mycoplasma.

In Vitro

Nystatin results in a significant reduction in buccal epithelial cell adhesion of all six Candida species\(^1\). Nystatin is an antibiotic that increases the permeability of plasma membranes to small monovalent ions, including chloride. Nystatin increases apical chloride permeability to the point where transepithelial chloride transport is limited by transport across the basolateral membrane of tracheal epithelial cells, which reflects primarily the activity of the cotransporter. Nystatin (400 units/mL) increases the basal level of transepithelial 36Cl\(^-\) flux approximately 1.5-fold and eliminates UTP stimulation of this flux. Nystatin treatment also abolishes UTP stimulation of saturable, basolateral \(^3\) H\(^-\)bumetanide binding, a measure of functioning Na-K-Cl cotransporters in these cells; isoproterenol stimulation of binding is only mildly inhibited by nystatin treatment\(^2\). Nystatin significantly enhances endostatin uptake by endothelial cells through switching endostatin internalization predominantly to the clathrin-mediated pathway.
Nystatin-enhanced internalization of endostatin also increases its inhibitory effects on endothelial cell tube formation and migration\(^3\).

**In Vivo**

Nystatin combined with endostatin selectively enhances endostatin uptake and biodistribution in tumor blood vessels and tumor tissues but not in normal tissues of tumor-bearing mice, ultimately resulting in elevated antiangiogenic and antitumor efficacies of endostatin in vivo\(^3\). Liposomal Nystatin, at doses as low as 2 mg/kg of body weight/day, protects neutropenic mice against Aspergillus-induced death in a statistically significant manner at the 50-day time point compared to either the no-treatment, the saline, or the empty-liposome group\(^4\).

---

**CUSTOMER VALIDATION**


See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

**REFERENCES**


---

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA